Jieming Zeng
Agency for Science, Technology and Research
29 Papers
302 Citations
Jieming Zeng is an academic researcher from Agency for Science, Technology and Research. The author has contributed to research in topics: Gene delivery & Induced pluripotent stem cell. The author has an hindex of 17, co-authored 29 publications. Previous affiliations of Jieming Zeng include National University of Singapore.
Chat about Author
Papers
Baculoviral Vector‐Mediated Transient and Stable Transgene Expression in Human Embryonic Stem Cells
TL;DR: It is reported here that baculoviral vectors were able to transduce hES cells efficiently and yielded stable transgene expression during the prolonged undifferentiated proliferation of h ES cells and after differentiation.
102
Self-assembled ternary complexes of plasmid DNA, low molecular weight polyethylenimine and targeting peptide for nonviral gene delivery into neurons.
Jieming Zeng,Xu Wang,Shu Wang +2 more
TL;DR: A new method for introducing targeting ligands into nonviral vectors, in which ternary complexes are formed via charge interactions among polyethylenimine (PEI) of 600Da, plasmid DNA and targeting peptides with positively charged DNA-binding sequence is described.
61
Large-scale expansion of Vγ9Vδ2 T cells with engineered K562 feeder cells in G-Rex vessels and their use as chimeric antigen receptor-modified effector cells.
Lin Xiao,Can Chen,Zhendong Li,Sumin Zhu,Johan Ck Tay,Xi Zhang,Shijun Zha,Jieming Zeng,Wee Kiat Tan,Xin Liu,Wee Joo Chng,Shu Wang +11 more
TL;DR: An efficient approach to generate highly functional Vγ9Vδ2 T cells in massive numbers suitable for clinical application in an allogeneic setting is reported.
54
Electroporation of NKG2D RNA CAR Improves Vγ9Vδ2 T Cell Responses against Human Solid Tumor Xenografts.
Wei Xia Ang,Yu Yang Ng,Lin Xiao,Can Chen,Zhendong Li,Zhixia Chi,Johan Chin-Kang Tay,Wee Kiat Tan,Jieming Zeng,Han Chong Toh,Shu Wang +10 more
TL;DR: Repeated doses of the CAR-expressing cells resulted in tumor regression in mice with established tumors, extending median survival time by up to 132% as compared to the PBS control group.
44
High mobility group box2 promoter-controlled suicide gene expression enables targeted glioblastoma treatment.
TL;DR: The results suggest that the novel 5' sequence of HMGB2 gene has a potential to be used as an efficient, tumor-selective promoter in targeted vectors for glioblastoma gene therapy.
41